Alembic Pharmaceuticals on Tuesday said its joint venture firm has received approval from the US health regulator to market Clobetasol Propionate shampoo, used in treatment of scalp psoriasis.
The company's joint venture, Aleor Dermaceuticals Ltd (Aleor), has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Alembic Pharma said in a regulatory filing.
The approved ANDA is generic version of Galderma Laboratories' Clobex Shampoo, which is indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older.
According to IQVIA, Clobetasol Propionate Shampoo, 0.05 per cent, has an estimated market size of USD 28 million for twelve months ending December 2019.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app